Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium difficile infection.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000009:adverse effects / Q000627:therapeutic use*; D000080908:Broadly Neutralizing Antibodies; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D012008:Recurrence; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000080908:Broadly Neutralizing Antibodies; C000613978:bezlotoxumab